LBRX
LB Pharmaceuticals Inc Common Stock- Healthcare
- Biotechnology
- $1.25B market cap
Forecast run · Oct 30, 2026Upside rank 812 of 3,167
Model Signal
ForecastQ Daily Probabilities
39.6%
46.4%
26.3%
Analyst Consensus
Recommendation2.25/5 Buy
Last price$38.73
Price target$59.78
Implied move+54.4%
Analysts4
ForecastQ Portfolios
LBRX is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.